Equal participation of minority patients in U.S. National Pediatric Cancer Clinical Trials

W. Archie Bleyer, Heriberto A. Tejeda, Sharon B. Murphy, Otis Brawley, Malcolm A. Smith, Richard S. Ungerleider

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the ethnic/racial distribution of patients entered in national pediatric cancer clinical trials relative to the patient population served. Methods: The ethnic/racial distribution of 29,134 patients <20 years of age entered in clinical trials conducted by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) between January 1, 1991 and June 30, 1994 were compared with the expected distribution of patients of the same age in the United States. The latter was predicted from the 1989 to 1991 crude incidence data of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program applied to the 1990 United States census. Results: Of the patients on CCG and POG trials, 11.6% were reported to be Hispanic, 10.4% were African-American, and 4.7% were other racial groups. The expected values were 9.1%, 10.7%, and 4.3%, respectively. Representation of minority patients was equal or greater than expected for 24 of 27 subgroups analyzed. Conclusions: In the United States, minority children with cancer are proportionately represented on clinical trials of the two national pediatric cancer cooperative groups. They and their families are provided with an equal opportunity to access clinical cancer trials and the potential benefits of cancer research.

Original languageEnglish (US)
Pages (from-to)423-427
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume19
Issue number5
DOIs
StatePublished - Sep 1 1997
Externally publishedYes

Fingerprint

Patient Participation
Clinical Trials
Pediatrics
Neoplasms
SEER Program
National Cancer Institute (U.S.)
Censuses
Hispanic Americans
African Americans
Incidence
Research
Population

Keywords

  • Minorities
  • Pediatric cancer trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Equal participation of minority patients in U.S. National Pediatric Cancer Clinical Trials. / Bleyer, W. Archie; Tejeda, Heriberto A.; Murphy, Sharon B.; Brawley, Otis; Smith, Malcolm A.; Ungerleider, Richard S.

In: Journal of Pediatric Hematology/Oncology, Vol. 19, No. 5, 01.09.1997, p. 423-427.

Research output: Contribution to journalArticle

Bleyer, W. Archie ; Tejeda, Heriberto A. ; Murphy, Sharon B. ; Brawley, Otis ; Smith, Malcolm A. ; Ungerleider, Richard S. / Equal participation of minority patients in U.S. National Pediatric Cancer Clinical Trials. In: Journal of Pediatric Hematology/Oncology. 1997 ; Vol. 19, No. 5. pp. 423-427.
@article{4ddbf0933ca8485ebb681ab8725f8493,
title = "Equal participation of minority patients in U.S. National Pediatric Cancer Clinical Trials",
abstract = "Purpose: To determine the ethnic/racial distribution of patients entered in national pediatric cancer clinical trials relative to the patient population served. Methods: The ethnic/racial distribution of 29,134 patients <20 years of age entered in clinical trials conducted by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) between January 1, 1991 and June 30, 1994 were compared with the expected distribution of patients of the same age in the United States. The latter was predicted from the 1989 to 1991 crude incidence data of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program applied to the 1990 United States census. Results: Of the patients on CCG and POG trials, 11.6{\%} were reported to be Hispanic, 10.4{\%} were African-American, and 4.7{\%} were other racial groups. The expected values were 9.1{\%}, 10.7{\%}, and 4.3{\%}, respectively. Representation of minority patients was equal or greater than expected for 24 of 27 subgroups analyzed. Conclusions: In the United States, minority children with cancer are proportionately represented on clinical trials of the two national pediatric cancer cooperative groups. They and their families are provided with an equal opportunity to access clinical cancer trials and the potential benefits of cancer research.",
keywords = "Minorities, Pediatric cancer trials",
author = "Bleyer, {W. Archie} and Tejeda, {Heriberto A.} and Murphy, {Sharon B.} and Otis Brawley and Smith, {Malcolm A.} and Ungerleider, {Richard S.}",
year = "1997",
month = "9",
day = "1",
doi = "10.1097/00043426-199709000-00003",
language = "English (US)",
volume = "19",
pages = "423--427",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Equal participation of minority patients in U.S. National Pediatric Cancer Clinical Trials

AU - Bleyer, W. Archie

AU - Tejeda, Heriberto A.

AU - Murphy, Sharon B.

AU - Brawley, Otis

AU - Smith, Malcolm A.

AU - Ungerleider, Richard S.

PY - 1997/9/1

Y1 - 1997/9/1

N2 - Purpose: To determine the ethnic/racial distribution of patients entered in national pediatric cancer clinical trials relative to the patient population served. Methods: The ethnic/racial distribution of 29,134 patients <20 years of age entered in clinical trials conducted by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) between January 1, 1991 and June 30, 1994 were compared with the expected distribution of patients of the same age in the United States. The latter was predicted from the 1989 to 1991 crude incidence data of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program applied to the 1990 United States census. Results: Of the patients on CCG and POG trials, 11.6% were reported to be Hispanic, 10.4% were African-American, and 4.7% were other racial groups. The expected values were 9.1%, 10.7%, and 4.3%, respectively. Representation of minority patients was equal or greater than expected for 24 of 27 subgroups analyzed. Conclusions: In the United States, minority children with cancer are proportionately represented on clinical trials of the two national pediatric cancer cooperative groups. They and their families are provided with an equal opportunity to access clinical cancer trials and the potential benefits of cancer research.

AB - Purpose: To determine the ethnic/racial distribution of patients entered in national pediatric cancer clinical trials relative to the patient population served. Methods: The ethnic/racial distribution of 29,134 patients <20 years of age entered in clinical trials conducted by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) between January 1, 1991 and June 30, 1994 were compared with the expected distribution of patients of the same age in the United States. The latter was predicted from the 1989 to 1991 crude incidence data of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program applied to the 1990 United States census. Results: Of the patients on CCG and POG trials, 11.6% were reported to be Hispanic, 10.4% were African-American, and 4.7% were other racial groups. The expected values were 9.1%, 10.7%, and 4.3%, respectively. Representation of minority patients was equal or greater than expected for 24 of 27 subgroups analyzed. Conclusions: In the United States, minority children with cancer are proportionately represented on clinical trials of the two national pediatric cancer cooperative groups. They and their families are provided with an equal opportunity to access clinical cancer trials and the potential benefits of cancer research.

KW - Minorities

KW - Pediatric cancer trials

UR - http://www.scopus.com/inward/record.url?scp=0031406504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031406504&partnerID=8YFLogxK

U2 - 10.1097/00043426-199709000-00003

DO - 10.1097/00043426-199709000-00003

M3 - Article

C2 - 9329463

AN - SCOPUS:0031406504

VL - 19

SP - 423

EP - 427

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 5

ER -